Key Investor Signals
Demonstrated nearly threefold faster closure in cell models
Founders co-authored a 2023 study in which direct current increased wound-gap closure nearly threefold in healthy and diabetic-like skin-cell models versus unstimulated controls.
Filed an international wound-dressing patent application
Bioelectrix is listed as applicant on WO2026041775A1, published in February 2026, covering a wound dressing combining electrical stimulation and measurements with adaptive control.
Secured early backing from Chalmers Ventures
University-linked deep-tech investor Chalmers Ventures added Bioelectrix to its portfolio in 2025, supporting the translation of its electrical wound-care technology.
Team
Caroline Kjærnet Johansen
CEO and Co-founder
- Completed a master’s degree in entrepreneurship at Chalmers School of Entrepreneurship, focused on developing research-led businesses.
- Served on the board of ICM Advice in 2024, a student consultancy advising researchers and startups on intellectual property and business development.
- Earned a bachelor’s degree in economics and administration, adding financial and organizational training to the founding team.
José Leal
CTO and Co-founder
- Trained in microsystems engineering at the University of Freiburg, specializing in microfabrication for biomedical devices.
- Researched electrodes and electronics for direct-current stimulation of cells in two- and three-dimensional cultures at Freiburg.
- Built more than eight years of experience across medical devices, electrical stimulation, biomaterials and biosensors.
Maria Asplund
Lead Scientific Advisor and Co-founder
- Led an independent research group at the University of Freiburg from 2011 to 2022 before becoming a Chalmers professor.
- Won European Research Council Starting and Proof of Concept grants supporting her bioelectronics research and technology translation.
- Built expertise in electronic biomaterials and tissue–device interactions, spanning wound repair and brain implants for visual restoration.
Product
Bioelectrix is developing wound electrodes that deliver controlled direct current to address bioelectric deficiencies in chronic wounds. The electrodes are designed to guide skin-cell migration and support wound closure, and are compatible with other wound technologies that address biochemical deficiencies. The lead application is diabetic foot ulcers, with sensing planned for later versions.
Conductive wound electrodes
Laser-induced graphene electrodes coated with a conducting polymer deliver sustained direct current. The materials are designed to support long stimulation periods while controlling unwanted electrochemical reactions.
Electrical guidance for skin cells
The electrodes apply a gentle electrical field intended to guide the movement of skin cells across a wound. This approach builds on laboratory research into the natural electrical cues involved in skin repair.
Wound-monitoring roadmap
The platform roadmap includes impedance, pH and temperature measurements to track wound conditions. Combining stimulation with sensing is intended to help clinicians follow progress and inform treatment decisions.
Market Overview
Advanced wound care is purchased by hospitals, specialist wound clinics and community-care providers managing wounds that require more than basic dressings. Products include moisture-managing dressings, biological skin substitutes and active wound therapies. Chronic wounds create demand for repeated treatment and effective closure.
Institutional procurement concentrates spending in hospitals, while prolonged treatment also extends into outpatient and home care. Clinicians select products according to wound type and healing progress; health systems evaluate treatment costs and resource use. Active dressings compete within this broader advanced-care category.
The global advanced wound-care market was estimated at $11.7B in 2025.
Hospitals accounted for an estimated 45.4% of global advanced wound-care revenue in 2025.
Chronic wounds represented an estimated 59.7% of global advanced wound-care revenue in 2025.
Global advanced wound-care revenue is forecast to grow 5.4% annually from 2026 to 2033.
Comparable Outcomes
Kerecis
Developed fish-skin grafts that help the body repair chronic, diabetic, burn, surgical, and trauma wounds. Coloplast completed the acquisition in August 2023. Terms comprised $1.2B upfront cash plus up to $100M contingent on financial performance.
Acelity
Acelity developed active wound-care systems and dressings, including KCI’s negative-pressure therapy that applies suction to support wound healing. 3M completed the purchase of Acelity and its KCI subsidiaries in October 2019.
Interested in More Startups Like Bioelectrix?
Get a curated pipeline of healthcare and life sciences startups aligned with your investment thesis.
Sources
This profile was built from public company materials, ecosystem sources, market references, and professional profiles.